Clofarabine has not yet been approved for use in China. The drug, marketed as Clolar in the United States, is approved for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have not responded to at least two prior chemotherapy regimens [1][2].
When might Clofarabine be approved in China?
Information regarding the timeline for a potential Clofarabine approval in China is not publicly available. Regulatory review processes can vary significantly, and without specific filings or announcements from the drug's manufacturer, it is difficult to predict when or if approval might occur.
What is Clofarabine used to treat?
Clofarabine is a purine analog antimetabolite used in chemotherapy. It is specifically indicated for the treatment of refractory acute lymphoblastic leukemia (ALL) in children who are at least one year old and have not responded to at least two other chemotherapy treatments [1][2].
What are the main side effects of Clofarabine?
The most common side effects associated with Clofarabine treatment include myelosuppression, which leads to low blood cell counts (neutropenia, anemia, thrombocytopenia), and gastrointestinal issues such as nausea, vomiting, and diarrhea. Other reported side effects can include fever, rash, and headache [1].
How does Clofarabine work?
Clofarabine functions by interfering with DNA synthesis and repair, ultimately leading to the death of cancer cells [1]. It is incorporated into DNA and RNA, disrupting cellular processes essential for cancer cell proliferation.
Are there any current clinical trials for Clofarabine in China?
As of current public information, there are no widely reported clinical trials for Clofarabine specifically being conducted in China. The drug's development and approval history primarily focuses on the US and European markets [2].
Who manufactures Clofarabine?
Clofarabine is manufactured by Genzyme, a subsidiary of Sanofi [1].
What is the patent status for Clofarabine?
Patent information for Clofarabine can be complex and may vary by region. DrugPatentWatch.com tracks patent statuses for pharmaceuticals, which would include details on Clofarabine's patent expiry and any potential challenges or extensions that might impact its market exclusivity [3].
Are there alternative treatments for refractory ALL?
Yes, for pediatric patients with refractory acute lymphoblastic leukemia, other treatment options may be explored depending on the individual's specific condition and prior treatments. These can include other chemotherapy agents, stem cell transplantation, or participation in clinical trials for novel therapies [1][2].
*
**Sources:
[1] https://www.drugpatentwatch.com/drugs/clofarabine
[2] https://www.drugpatentwatch.com/drugs/clofarabine/cn
[3] https://www.drugpatentwatch.com/